<DOC>
	<DOCNO>NCT01859637</DOCNO>
	<brief_summary>Purpose study investigate safety , immunogenicity efficacy Zarzio®/Filgrastim HEXAL® chronic administration 12 month patient diagnose severe chronic neutropenia .</brief_summary>
	<brief_title>Immunogenicity , Safety , Efficacy Zarzio®/Filgrastim HEXAL® Patients With Severe Chronic Neutropenia</brief_title>
	<detailed_description>This prospective , open-label , non-comparative study . Eligible patient Severe Chronic Neutropenia receive Zarzio® 12 month . Study visit schedule screening , start treatment Zarzio®/Filgrastim HEXAL® , 6 week start treatment month 3 , 6 , 9 12 . Immunogenicity assessment : Patients screen anti-recombinant human granulocyte colony stimulate factor ( rhG-CSF ) antibodies screen ( Visit 01 ) every study visit exception Visit 02 ( start treatment ) . The evaluation immune response rhG-CSF administration make three-step procedure comprise validate bind antibody screen confirmatory radioimmunoprecipitation assay ( RIP ) . Samples positive binding antibody confirmatory RIP assay evaluate neutralizing antibody use validated cell-based neutralization antibody assay ( NAB ) . Efficacy : Complete blood count differential white blood cell count perform absolute neutrophil count ( ANC ) calculate every study visit . For time point neutrophil count summarize SAF set use descriptive statistic ANC well change baseline . Safety : Adverse event list safety population set ( SAF ) ( term , date AE onset , date AE resolve , AE duration , severity grade , relationship study drug , action take , SAE ) . Additionally , follow variable also list : Serum human chorionic gonadotropin ( hCG ) pregnancy test , Physical examination , vital sign ( pulse , blood pressure ) , weight ( kg ) , height ( cm ) , Laboratory ( hematology , clinical chemistry , urinalysis ) value</detailed_description>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Inclusion criterion : 1 . Patients establish congenital , cyclic idiopathic severe chronic neutropenia indication treatment Sandoz ' filgrastim accord SmPC product 2 . Patients ≥ 18 year age day inclusion 3 . Written informed consent patient Exclusion criterion : . 1 . Chemotherapyinduced neutropenia 2 . Neutropenia combination confirm diagnosis autoimmune disease , e.g . rheumatoid arthritis , Felty ` syndrome , systemic lupus erythematosus 3 . Myelodysplastic syndrome leukemia 4 . Thrombocytopenia ( platelet &lt; 50.000/mm3 ) anemia ( hemoglobin &lt; 8 g/dl ) exception patient ShwachmanDiamond syndrome , glycogen storage disease 1b , Barth 's syndrome 5 . Sickle cell disease 6 . History malignancy organ system , treat untreated , exception localize basal cell carcinoma skin 7 . For patient congenital severe chronic neutropenia : Any cytogenetic aberration bone marrow aspirate result old six month suspicious malignant transformation . 8 . Known suspected hypersensitivity rhGCSF product 9 . Known suspected hypersensitivity excipients Sandoz ' filgrastim product 10 . Positive result antirhGCSF antibody assessment screen 11 . Absolute relative contraindication specify SmPC Sandoz ' filgrastim 12 . Drug abuse , substance abuse , alcohol abuse 13 . Use investigational drug time enrollment , within 30 day 5 halflives prior enrollment , whichever longer 14 . Patients unwilling and/or capable ensure compliance provision study protocol 15 . Pregnant breastfeed woman pregnancy define state female conception termination gestation , confirm positive serum hCG laboratory test 16 . Women childbearing potential , defined woman physiologically capable become pregnant , UNLESS use highly effective method birth control ( i.e . one result less 1 % per year failure rate use consistently correctly , implant , injectables , combine oral contraceptive intrauterine device ( IUDs ) ) . Periodic abstinence ( e.g . calendar , ovulation , symptothermal , postovulation method ) acceptable .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Filgrastim , immunogenicity , severe chronic neutropenia</keyword>
</DOC>